Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anticancer Agents
Identification of best doses requires attention to dose limiting toxic events
October 27th, 2003
Identification of best doses requires attention to dose limiting toxic events. According to a study from the United States, "Certain toxic effects of cytotoxic anticancer agents typically evolve over weeks. When such agents are administered weekly, these effects are cumulative. "With such schedules, good medical practice mandates dose modifications with mild or moderate toxicity in order to avoid progression to serious or life-threatening toxicity. These modifications lead to differences between scheduled and delivered doses. Phase I studies are designed to identify the maximum tolerated dose for a given schedule," wrote D.K. McClish and colleagues,...
Source: Health & Medicine Week (2003-10-27)
|
